Avacta Group, the developer of Affimer biotherapeutics and reagents, has initiated a research collaboration with FIT Biotech Oy to assess the effectiveness of developing gene therapies using Avacta's Affimer technology combined with FIT Biotech's gtGTU platform.

Avacta Group chief executive officer Dr Alastair Smith said: 'I am delighted that we are starting this collaboration with FIT Biotech.

'The Affimer technology is an ideal platform for gene delivery, and working with FIT Biotech's powerful gtGTU vector technology could lead to multiple therapeutic benefits and create a best-in-class gene therapy combination with significant potential.

'It is a very exciting prospect and the Group is keen to see the initial data from the pilot study which we anticipate will be in the first half of 2018.'






At 8:56am: (LON:AVCT) Avacta Group PLC share price was +1.5p at 68.5p